![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Seoul National University Hospital H. Lundbeck A/S |
---|---|
Information provided by: | Seoul National University Hospital |
ClinicalTrials.gov Identifier: | NCT00702780 |
The purpose of this study is to verify the progression delaying effect of escitalopram in Alzheimer's disease using volumetric MRI change as a primary outcome measure.
Condition | Intervention |
---|---|
Alzheimer's Disease |
Drug: escitalopram Drug: placebo |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Multi-Center, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease |
Estimated Enrollment: | 80 |
Study Start Date: | November 2008 |
Estimated Study Completion Date: | November 2010 |
Estimated Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
escitalopram 20mg
|
Drug: escitalopram
5mg/day for 2weeks, 10mg/day for 2weeks and 20mg/day for 48weeks (maintaining donepezil at the previous stable dose during the whole trial period)
|
2: Placebo Comparator
Placebo
|
Drug: placebo
5mg/day for 2weeks, 10mg/day for 2weeks and 20mg/day for 48weeks (maintaining donepezil at the previous stable dose during the whole trial period)
|
Ages Eligible for Study: | 40 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Contact: Dong Young Lee, MD, PhD | 82-2-2072-2205 | selfpsy@snu.ac.kr |
Contact: IL Han Choo, MD, PhD | 82-2-2072-1630 | npchoo10@snu.ac.kr |
Korea, Republic of | |
Seoul National University Hospital | Recruiting |
Seoul, Korea, Republic of, 110-744 | |
Contact: IL Han Choo, MD, PhD +82-2-2072-1630 npchoo10@snu.ac.kr | |
Principal Investigator: Jong Inn Woo, MD, PhD | |
Seoul National University Bundang Hospital | Active, not recruiting |
Seongnam, Korea, Republic of | |
Kangwon National University Hospital | Active, not recruiting |
Chuncheon, Korea, Republic of | |
Konkuk University Hospital | Active, not recruiting |
Seoul, Korea, Republic of |
Principal Investigator: | Dong Young Lee, MD, PhD | Dept. of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine |
Principal Investigator: | Jong Inn Woo, MD, PhD | Dept. of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine |
Responsible Party: | Seoul National University Hospital ( Dong Young Lee / Associate Professor of Neuropsychiatry ) |
Study ID Numbers: | SNUDC001 |
Study First Received: | June 15, 2008 |
Last Updated: | November 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00702780 History of Changes |
Health Authority: | Korea: Food and Drug Administration |
Alzheimer's disease escitalopram MRI |
Neurotransmitter Agents Cholinergic Antagonists Alzheimer Disease Psychotropic Drugs Disease Progression Central Nervous System Diseases Cholinergic Agents Brain Diseases Neurodegenerative Diseases Serotonin Uptake Inhibitors Citalopram Serotonin |
Cognition Disorders Muscarinic Antagonists Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Donepezil Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Dementia Dexetimide Antidepressive Agents Delirium |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Neurodegenerative Diseases Brain Diseases Cholinergic Agents Mental Disorders Therapeutic Uses Antidepressive Agents, Second-Generation |
Dexetimide Dementia Antidepressive Agents Nervous System Diseases Alzheimer Disease Central Nervous System Diseases Serotonin Uptake Inhibitors Citalopram Pharmacologic Actions Muscarinic Antagonists Serotonin Agents Delirium, Dementia, Amnestic, Cognitive Disorders Autonomic Agents Peripheral Nervous System Agents Tauopathies |